Harrow Health, Inc. is officially no more—the company announced it has dropped “Health” from its corporate name to become Harrow, Inc.
Refresh me on this company.
Launched in 2014 and based in Nashville, Tennessee, the publicly-traded ophthalmic pharmaceutical company is a manufacturer and distributor of pharmaceutical products for ophthalmic surgeries as well as prescription-based medications for managing chronic and acute eye conditions.
To note, Harrow also owns ImprimisRx, LLC—a San Diego, California-based specialty pharmaceutical company focused on developing and commercializing proprietary and novel sterile and topical drug formulations.
Gotcha. So why the name change?
Per the company, it’s to align with Harrow’s 5-year plan to focus exclusively on eyecare pharmaceuticals.
With its recent ophthalmic acquisitions in the last year, it’s safe to say the company is on target toward that goal. And as CEO Mark L. Baum stated, Harrow now has, “one of the largest portfolios of ophthalmic pharmaceutical products in the U.S. market.”
Talk about this portfolio.
In January 2023, Harrow acquired the exclusive U.S. rights to five FDA-approved branded ophthalmics from Novartis (the second deal between the two companies in less than a year):
- Ilevro (nepafenac ophthalmic suspension) 0.3%
- Nevanac (nepafenac ophthalmic suspension) 0.1%
- Vigamox (moxifloxacin hydrochloride ophthalmic suspension) 0.5%
- Maxidex (dexamethasone ophthalmic suspension) 0.1%
- Triesence (triamcinolone acetonide injectable suspension) 40 mg/ml
To note, the company launched Ilevro, Nevanac, and Maxidex in May 2023 and Vigamox in August 2023.
The new drug application (NDA) transfer for Triesence is expected by the end of 2023.
What else?
In February 2023, the company launched—via ImprimisRx—a compounded, next-generation, patent-pending (and not FDA-approved) formulation of atropine for the potential indications of cycloplegia, mydriasis, amblyopia, and uveitis.
Read the details here.
Any other launches?
One more! Iheezo (chloroprocaine hydrochloride ophthalmic gel) 3% was also launched in May 2023 as the first branded ocular aesthetic approved in the U.S. in 14 years.
Read our coverage here.
Any other acquisitions?
Yup, just a few more:
July 2023 saw quite a bit of activity, with Harrow purchasing the U.S. and Canadian commercial rights to Novaliq’s VEVYE (cyclosporine ophthalmic solution) 0.01%, newly-FDA-approved (in May 2023) as the first and only cyclosporine water- and preservative-free solution indicated for dry eye disease (DED) treatment. See the coverage here.
And in the span of just days, the company also announced it was acquiring the U.S. and Canadian commercial rights for seven specific ophthalmic products from Santen Pharmaceutical Co., Ltd. See here for the rundown.